Goldman Sachs
ACIU icon

Goldman Sachs’s AC Immune ACIU Stock Holding History

Goldman Sachs’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,700
Closed -$199K – 5450
2020
Q3 		$199K Buy
+40,700
New +$292K ﹤0.01% 4913

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs's ACIU Position: Q1 2026 in Review

Goldman Sachs increased its AC Immune (ACIU) stake by 17% in Q1 2026, buying an estimated $9.55K and bringing the position to 21,632 shares worth $59.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6279.

Goldman Sachs first reported a position in ACIU in Q3 2016 and has held it in 28 quarters since. The position peaked at $479K in Q3 2016. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.

  • Goldman Sachs held 21,632 shares of AC Immune worth $59.5K as of Q1 2026.
  • Goldman Sachs bought 3,077 AC Immune shares in Q1 2026, an estimated $9.55K.
  • AC Immune made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6279 holding.
  • Goldman Sachs first reported a position in AC Immune in Q3 2016 and has held it in 28 quarters since.
  • Goldman Sachs's AC Immune position peaked at $479K in Q3 2016.
  • 46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.